I just went through the BK report and I am literal
Post# of 36537
(Total Views: 382)
Posted On: 10/20/2022 2:23:59 PM
I just went through the BK report and I am literally amazed that with everything that Generex had / has under their belt they did not succeed. Honestly, this company should have been a giant of a company.
Yet, look at where it is at. Actually, look at where we are at. This should be a textbook look on how a company is run, how a board of directors sits around, how so much became so wasted.
You can look at each piece of Generex, look at each company within Generex and see so much potential for the most part. Much like spokes in a wheel. The biggest problem, was that the management was the tire and it was flat. A slow leak, then steady, then a big blowout.
The wound care had so much potential in multiple areas. The diabetes is the same. The Cancer drug can be major and lead to so many other areas and Generex literally blew that one big time.
The list goes on and on and on.
The reality is, is that focus was a huge problem. Communication was a major problem. Leadership was the biggest problem.
Hopefully, NGIO can at least deliver something out of all of this mess. I am not sure how the wound care, diabetes, or anything else will impact us, but right now, Generex is the new ship that hit the iceberg and there is no captain at the helm.
Yet, look at where it is at. Actually, look at where we are at. This should be a textbook look on how a company is run, how a board of directors sits around, how so much became so wasted.
You can look at each piece of Generex, look at each company within Generex and see so much potential for the most part. Much like spokes in a wheel. The biggest problem, was that the management was the tire and it was flat. A slow leak, then steady, then a big blowout.
The wound care had so much potential in multiple areas. The diabetes is the same. The Cancer drug can be major and lead to so many other areas and Generex literally blew that one big time.
The list goes on and on and on.
The reality is, is that focus was a huge problem. Communication was a major problem. Leadership was the biggest problem.
Hopefully, NGIO can at least deliver something out of all of this mess. I am not sure how the wound care, diabetes, or anything else will impact us, but right now, Generex is the new ship that hit the iceberg and there is no captain at the helm.
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼